Sagar R et al (2020) The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990–2017. Lancet Psychiatry 7(2):148–161

Article  Google Scholar 

Ermakov EA et al (2022) Immune system abnormalities in schizophrenia: an integrative view and translational perspectives. Front Psychiatry 13:21

Article  Google Scholar 

Du Y et al (2022) Exploration of the relationship between hippocampus and immune system in schizophrenia based on immune infiltration analysis. Front Immunol 13:878997

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh D et al (2022) Changes in leukocytes and CRP in different stages of major depression. J Neuroinflamm 19(1):74

Article  CAS  Google Scholar 

Werner MCF et al (2022) Limited association between infections, autoimmune disease and genetic risk and immune activation in severe mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 116:110511

Article  CAS  PubMed  Google Scholar 

Muller N (2018) Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull 44(5):973–982

Article  PubMed  PubMed Central  Google Scholar 

Khandaker GM et al (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2(3):258–270

Article  PubMed  PubMed Central  Google Scholar 

Hong J, Bang M (2020) Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing. Clin Psychopharmacol Neurosci 18(1):10–24

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M et al (2022) Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 272(4):633–642

Article  PubMed  Google Scholar 

Sommer IE et al (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40(1):181–191

Article  PubMed  Google Scholar 

Tomasik J et al (2016) Neuroimmune biomarkers in schizophrenia. Schizophr Res 176(1):3–13

Article  PubMed  Google Scholar 

Naude PJW et al (2013) Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. J Psychosom Res 75(5):444–450

Article  CAS  PubMed  Google Scholar 

Naude PJW et al (2021) Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer’s disease dementia. Neurobiol Aging 107:1–10

Article  CAS  PubMed  Google Scholar 

Raposo-Lima C et al (2021) Elevated levels of neutrophil gelatinase-associated lipocalin among OCD patients: an exploratory study. BMC Psychiatry 21(1):6

Article  Google Scholar 

Wei L et al (2018) Elevation of plasma neutrophil gelatinase-associated lipocalin (NGAL) levels in schizophrenia patients. J Affect Disord 226:307–312

Article  CAS  PubMed  Google Scholar 

Lee EE et al (2017) Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Am J Geriatr Psychiatry 25(1):50–61

Article  PubMed  Google Scholar 

Lesh TA et al (2018) Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflamm 15:11

Article  Google Scholar 

Al-Asmari AK, Khan MW (2014) Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol 33(2):115–122

Article  CAS  PubMed  Google Scholar 

Azizi E et al (2019) Alteration of serum levels of cytokines in schizophrenic patients before and after treatment with risperidone. Iran J Allergy Asthma Immunol 18(3):262–268

PubMed  Google Scholar 

Frydecka D et al (2018) Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain Behav Immun 71:28–36

Article  PubMed  Google Scholar 

Arrais AC et al (2022) S100B protein: general characteristics and pathophysiological implications in the central nervous system. Int J Neurosci 132(3):313–321

Article  CAS  PubMed  Google Scholar 

Chong ZZ et al (2016) Identifying S100B as a biomarker and a therapeutic target for brain injury and multiple diseases. Curr Med Chem 23(15):1571–1596

Article  CAS  PubMed  Google Scholar 

Hong W et al (2016) Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers. Sci Rep 6:27584

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan J et al (2022) Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma. PeerJ 10:e13201

Article  PubMed  PubMed Central  Google Scholar 

Lara DR et al (2001) Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 35(1):11–14

Article  CAS  PubMed  Google Scholar 

Rothermundt M et al (2001) Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6(4):445–449

Article  CAS  PubMed  Google Scholar 

Rothermundt M et al (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29(5):1004–1011

Article  CAS  PubMed  Google Scholar 

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276

Article  CAS  PubMed  Google Scholar 

Shi C et al (2015) The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res 169(1–3):109–115

Article  PubMed  PubMed Central  Google Scholar 

Deng HQ et al (2018) Elevated plasma S100B, psychotic symptoms, and cognition in schizophrenia. Psychiatr Q 89(1):53–60

Article  PubMed  Google Scholar 

Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428

Article  CAS  PubMed  Google Scholar 

Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P (2013) S100B and schizophrenia. Psychiatry Clin Neurosci 67(2):67–75

Article  CAS  PubMed  Google Scholar 

Wiesmann M et al (1999) Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45(11):1508–1511

Article  CAS  PubMed  Google Scholar 

Steiner J et al (2013) Potential roles of S100B in schizophrenia. Revista De Psiquiatria Clinica 40(1):35–40

Article  Google Scholar 

Kozlowska E et al (2021) Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. J Psychiatr Res 138:380–387

Article  PubMed  Google Scholar 

Liu X et al (2018) Serum or plasma, what is the difference? Investigations to facilitate the sample material selection decision making process for metabolomics studies and beyond. Anal Chim Acta 1037:293–300

Article  CAS  PubMed  Google Scholar 

Borregaard N, Sørensen OE, Theilgaard-Mönch K (2007) Neutrophil granules: a library of innate immunity proteins. Trends Immunol 28(8):340–345

Article  CAS  PubMed  Google Scholar 

Marakala V (2022) Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury—a systematic review. Clin Chim Acta 536:135–141

Article  CAS  PubMed  Google Scholar 

Buonafine M, Martinez-Martinez E, Jaisser F (2018) More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin Sci (Lond) 132(9):909–923

Article  CAS  PubMed  Google Scholar 

Naudé PJW et al (2013) Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. J Psychosom Res 75(5):444–450

Article  PubMed  Google Scholar 

Pillny M et al (2022) From memories of past experiences to present motivation? A meta-analysis on the association between episodic memory and negative symptoms in people with psychosis. Schizophr Bull 48(2):307–324